Travere Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 697.79, 968.86, 1183.42, 1488.81, 1766.69 ], "ebit_estimate": [ 8.17, 264, 258.99, 506.36, 662.52 ], "ebitda_estimate": [ -2.63, 500.3, 577.82, 702.91, 859.77 ], "net_income_estimate": [ 11.33, 170.75, 297.1, 483.21, 590.35 ], "per_share_eps_estimate": [ 0.26, 2.3, 2.75, 4.23, 4.8 ], "eps_nri_estimate": [ 0.22, 1.64, 2.75, 4.23, 4.8 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 1.83, 3.96, null, null, null ], "pretax_income_estimate": [ 83.2, 266.57, 418.88, 703.02, 958.56 ], "operating_cash_flow_per_share_estimate": [ 1.03, 3.6, null, null, null ], "roa_estimate": [ -4.4, 22.2, null, null, null ], "roe_estimate": [ 12.48, 222.99, 86.67, null, null ], "gross_margin_estimate": [ 93.74, 92.54, 90.35, 90.3, 89.15 ], "operating_cash_flow_estimate": [ 94.17, 330.73, null, null, null ], "pettm_estimate": [ 215.21, 24.62, 20.61, 13.37, 11.79 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "34.57", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 34.57, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -2.53, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 160.66, 181.73, 231.35, 209.52, 238.28, 262.69, 287.93 ], "ebit_estimate": [ 3.8, 12.97, 64.35, 32.85, 41.4, 64.85, 88.7 ], "ebitda_estimate": [ 40.06, 27.45, 42.14, 104.97, 140.48, 157.75, 168.4 ], "net_income_estimate": [ -9.57, 0.88, 53.36, 38.08, 61.35, 76.74, 107.48 ], "per_share_eps_estimate": [ -0.1, 0.01, 0.51, 0.4, 0.65, 0.8, 1.11 ], "eps_nri_estimate": [ -0.11, -0.03, 0.49, 0.32, 0.49, 0.63, 1.05 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -1.6, 2.53, 65.24, 55.23, 75.07, 95.23, 134.57 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ 87.42, 88.16, 95.3, null, null, null, null ], "gross_margin_estimate": [ 92.48, 92.43, 90.55, 95.5, 95.5, 95.5, 95.5 ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 68.86, 36.17, 24.02, 19.1, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "34.57", "future_per_share_eps_estimate_growth": null, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": 34.57, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": null, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -2.53, "future_operating_cash_flow_per_share_estimate_growth": null }